SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

Clinical and Translational Oncology

Volumn 15, Issue 12, 2013, Pages 1018-1024

  Mesia R ^a   Pastor, M ^b   Grau, J J ^c   Del Barco, E ^d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Cetuximab; EXTREME ERBITAX; Head and neck cancer; Induction chemotherapy; TPF

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ARTICLE; BRACHYTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; LARYNGECTOMY; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; THORAX RADIOGRAPHY; TUMOR BIOPSY;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84888203755     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1096-z     Document Type: Article

References (19)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality in Europe: estimates for 40 countries in 2012. Eur J Cancer (online version). 2013. doi: 10.1016/j.ejca.2012.12.027.
2. TNM Classification. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
3. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890-900.
4. Winquist E, Oliver T, Gilvert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck. 2007;29:38-46.
5. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer. Lancet. 2000;355:949-55.
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-78.
7. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-8.
8. Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesía R, Degardin M, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. Phase III trial EORTC 24971/TAX 323. NEJM. 2007;357:1695-704.
9. Posner MR, Hershock DM, Blajman CR, Michiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. TAX 324 Study Group. NEJM. 2007;357:1705-25.
10. Lefebvre JL, And KK. Larynx preservation clinical trial design: key issues and recommendations. A consensus panel summary. Int J Radiation Oncol Biol Phys. 2009;73:1293-303.
11. VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Departament of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685-90.
12. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-8.
13. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31:845-52.
14. Pointreau Y, Garuad P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer. 2009;101:498-506.
15. Bonner JA, Harari M, Giralt J, Baselga J, Shin D, Cohen R et al. Improved preservation of larynx with the addition of cetuximab to radiotherapy for cancers of the larynx and hypopharynx. J Clin Oncol. 2005;23(16S):5533.
16. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853-9.
17. Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-45.
18. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27.
19. Hitt R, Irigoyen A, Cortes Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016-22.